Arrivent Biopharma, Inc. · NASDAQ:AVBP
Octagon Capital Advisors LP's stake in Arrivent Biopharma, Inc. fell to 4.90% (Schedule 13G/A)
Event Sep 30, 2025 · Filed Nov 14, 2025
Octagon Capital Advisors LP's stake in Arrivent Biopharma, Inc. fell to 4.90%, 1,971,054 shares, as a passive investor on Sep 30, 2025. Filed Nov 14, 2025 (Schedule 13G/A).
- Stake
- 4.90%
- Shares
- 1,971,054
- Intent
- Passive
- What changed
- Fell below 5%
- Filed together
- 5 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Octagon Capital Advisors LP | 4.90% | 1,971,054 |
| Octagon Investments Master Fund LP | 1.90% | 776,667 |
| Octagon Private Opportunities Fund LP | 2.00% | 799,911 |
| Octagon Special Opportunities Fund LP - Series 4 | 1.00% | 394,476 |
| Ting Jia | 4.90% | 1,971,054 |
Source
Related
- Arrivent Biopharma, Inc.
- Octagon Capital Advisors LP
- Arrivent Biopharma, Inc. shareholders
- Schedule 13G · Vivo Opportunity, LLC · Oct 13, 2026
- Schedule 13D/A · Orbimed Advisors LLC · Oct 8, 2026
- Schedule 13G/A · BlackRock, Inc. · Jul 27, 2026
- Schedule 13G/A · FMR LLC · May 6, 2026
- Schedule 13G/A · Sofinnova Venture Partners IX, L.P. ("SVP IX") · Mar 5, 2026